{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:06:15Z","timestamp":1790676375444,"version":"4.1.0"},"reference-count":401,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162249"],"award-info":[{"award-number":["PJT-162249"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The ubiquitin-proteasome system (UPS) is a critical regulator of cellular protein levels and activity. It is, therefore, not surprising that its dysregulation is implicated in numerous human diseases, including many types of cancer. Moreover, since cancer cells exhibit increased rates of protein turnover, their heightened dependence on the UPS makes it an attractive target for inhibition via targeted therapeutics. Indeed, the clinical application of proteasome inhibitors in treatment of multiple myeloma has been very successful, stimulating the development of small-molecule inhibitors targeting other UPS components. On the other hand, while the discovery of potent and selective chemical compounds can be both challenging and time consuming, the area of targeted protein degradation through utilization of the UPS machinery has seen promising developments in recent years. The repertoire of proteolysis-targeting chimeras (PROTACs), which employ E3 ligases for the degradation of cancer-related proteins via the proteasome, continues to grow. In this review, we will provide a thorough overview of small-molecule UPS inhibitors and highlight advancements in the development of targeted protein degradation strategies for cancer therapeutics.<\/jats:p>","DOI":"10.3390\/cancers13123079","type":"journal-article","created":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T22:00:02Z","timestamp":1624226402000},"page":"3079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors"],"prefix":"10.3390","volume":"13","author":[{"given":"Gabriel","family":"LaPlante","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Rd E, Guelph, ON N1G2W1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5813-240X","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Rd E, Guelph, ON N1G2W1, Canada"},{"name":"CIFAR Azrieli Global Scholars Program, Canadian Institute for Advanced Research, MaRS Centre West Tower, 661 University Avenue, Toronto, ON M5G1M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.dnarep.2017.06.011","article-title":"Histone ubiquitination in the DNA damage response","volume":"56","author":"Uckelmann","year":"2017","journal-title":"DNA Repair"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/35056583","article-title":"Protein regulation by monoubiquitin","volume":"2","author":"Hicke","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/cmi.2016.15","article-title":"Regulation of inflammasomes by ubiquitination","volume":"13","author":"Bednash","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ddtec.2017.11.006","article-title":"Tools to investigate the ubiquitin proteasome system","volume":"26","author":"Leestemaker","year":"2017","journal-title":"Drug Discov. Today Technol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.trecan.2019.08.005","article-title":"DUBs, Hypoxia, and Cancer","volume":"5","author":"Mennerich","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj20040198","article-title":"Getting into position: The catalytic mechanisms of protein ubiquitylation","volume":"379","author":"Passmore","year":"2004","journal-title":"Biochem. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00018-008-8090-6","article-title":"Polyubiquitin chains: Functions, structures, and mechanisms","volume":"65","author":"Li","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8894","DOI":"10.1073\/pnas.1610186113","article-title":"Monoubiquitination in proteasomal degradation","volume":"113","author":"Ronai","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nakamura, N. (2018). Ubiquitin System. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041080"},{"key":"ref_10","first-page":"1","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","article-title":"Breaking the chains: Deubiquitylating enzyme specificity begets function","volume":"20","author":"Clague","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: Structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10555-017-9697-6","article-title":"Proteasome-associated deubiquitinases and cancer","volume":"36","author":"Mofers","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.200810114","article-title":"K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway","volume":"185","author":"Lauwers","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-020-00245-6","article-title":"Beyond K48 and K63: Non-canonical protein ubiquitination","volume":"26","author":"Tracz","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm1701","article-title":"Ubiquitin-binding domains","volume":"6","author":"Hicke","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, X., Linder, S., and Bazzaro, M. (2020). Drug Development Targeting the Ubiquitin\u2013Proteasome System (UPS) for the Treatment of Human Cancers. Cancers, 12.","DOI":"10.3390\/cancers12040902"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3389\/fimmu.2019.01751","article-title":"The Membrane-Associated MARCH E3 Ligase Family: Emerging Roles in Immune Regulation","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A Genomic and Functional Inventory of Deubiquitinating Enzymes","volume":"123","author":"Nijman","year":"2005","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: Structure and function of the deubiquitinases","volume":"10","author":"Komander","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2011.443","article-title":"Deubiquitinases in cancer: New functions and therapeutic options","volume":"31","author":"Fraile","year":"2012","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2018.03.022","article-title":"In a Class of Its Own: A New Family of Deubiquitinases Promotes Genome Stability","volume":"70","author":"Coleman","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/15384101.2017.1288326","article-title":"The importance of regulatory ubiquitination in cancer and metastasis","volume":"16","author":"Gallo","year":"2017","journal-title":"Cell Cycle"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrc1881","article-title":"Ubiquitin ligases: Cell-cycle control and cancer","volume":"6","author":"Nakayama","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.1162981","article-title":"FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression","volume":"321","author":"Mao","year":"2008","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ceb.2011.05.007","article-title":"Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation","volume":"23","author":"Karbowski","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.embor.7400790","article-title":"MARCH-V is a novel mitofusin 2- and Drp1-binding protein able to change mitochondrial morphology","volume":"7","author":"Nakamura","year":"2006","journal-title":"EMBO Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.celrep.2018.05.013","article-title":"Ubiquitin-Dependent Degradation of Mitochondrial Proteins Regulates Energy Metabolism","volume":"23","author":"Lavie","year":"2018","journal-title":"Cell Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"R110-006924","DOI":"10.1074\/mcp.M110.006924","article-title":"Oxidative Stress-Mediated Regulation of Proteasome Complexes","volume":"10","author":"Aiken","year":"2011","journal-title":"Mol. Cell. Proteom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cub.2007.01.027","article-title":"Ubiquitination of RIP1 Regulates an NF-\u03baB-Independent Cell-Death Switch in TNF Signaling","volume":"17","author":"Skountzos","year":"2007","journal-title":"Curr. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","article-title":"Ubiquitin-Proteasome System Stress Sensitizes Ovarian Cancer to Proteasome Inhibitor\u2013Induced Apoptosis","volume":"66","author":"Bazzaro","year":"2006","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2019.03.003","article-title":"Emerging drug development technologies targeting ubiquitination for cancer therapeutics","volume":"199","author":"Veggiani","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev-pharmtox-010715-103507","article-title":"Targeted Protein Degradation by Small Molecules","volume":"57","author":"Bondeson","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_35","first-page":"438","article-title":"Targeting the ubiquitin system in cancer therapy","volume":"458","author":"Hoeller","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies","volume":"15","author":"Stewart","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_40","first-page":"179","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP","volume":"467","author":"Lee","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"Brnjic","year":"2011","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26979","DOI":"10.1038\/srep26979","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/1078-0432.CCR-13-2658","article-title":"Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses","volume":"20","author":"Coughlin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","article-title":"Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis","volume":"70","author":"Kapuria","year":"2010","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","article-title":"A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13\/ADRM1 as a Therapy for Cancer","volume":"24","author":"Anchoori","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-\u03baB in cancer: From innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-\u03baB as a Therapeutic Target in Multiple Myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_49","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-\u03baB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_50","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biochi.2008.10.015","article-title":"Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels","volume":"91","author":"Baiz","year":"2009","journal-title":"Biochimie"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00280-016-2997-7","article-title":"A phase II, open-label trial of bortezomib (VELCADE\u00ae) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer","volume":"77","author":"Kontopodis","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter Phase II Study of Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/glia.21065","article-title":"Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy","volume":"58","author":"Shin","year":"2010","journal-title":"Glia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Suzuki, E., Demo, S., Deu, E., Keats, J., Arastu-Kapur, S., Bergsagel, P.L., Bennett, M.K., and Kirk, C.J. (2011). Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027996"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: Proteasome subunit \u03b25 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/BST20190535","article-title":"Small molecules that target the ubiquitin system","volume":"48","author":"Wu","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.13243","article-title":"A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation","volume":"169","author":"Girnius","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ejh.13281","article-title":"Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials","volume":"103","author":"Straka","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/leu.2014.27","article-title":"Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy","volume":"28","author":"Berenson","year":"2014","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/leu.2016.186","article-title":"Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study","volume":"31","author":"Moreau","year":"2016","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.26088","article-title":"A phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed\/refractory multiple myeloma: Final analysis of second dose-expansion cohort","volume":"96","author":"Berdeja","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"106172","DOI":"10.1016\/j.leukres.2019.106172","article-title":"Efficacy and safety results from a phase 1b\/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"83","author":"Hari","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies","volume":"17","author":"Lee","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41416-019-0581-8","article-title":"Ixazomib\u2013Thalidomide\u2013Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed\/refractory multiple myeloma","volume":"121","author":"Ludwig","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-017-0524-3","article-title":"Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed\/Refractory Multiple Myeloma: Clinical and Model-Based Analyses","volume":"12","author":"Gupta","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41422-018-0091-x","article-title":"Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade","volume":"28","author":"Wang","year":"2018","journal-title":"Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bcp.2018.08.039","article-title":"The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage","volume":"156","author":"Zhang","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2010-03-276477","article-title":"Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis","volume":"117","author":"Sun","year":"2011","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"160","DOI":"10.18632\/oncotarget.27869","article-title":"Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma","volume":"12","author":"Potu","year":"2021","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-10-0238","article-title":"Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications","volume":"9","author":"Pham","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2019.03.046","article-title":"Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress","volume":"453","author":"Akiyama","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.chembiol.2018.07.012","article-title":"Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn","volume":"25","author":"Li","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_81","first-page":"732","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-\u03baB\u2013dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Brief report Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s10637-020-01017-x","article-title":"Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors","volume":"39","author":"Zhou","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/bcp.14078","article-title":"Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies","volume":"85","author":"Faessel","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10637-018-0610-0","article-title":"Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors","volume":"37","author":"Lockhart","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2011.05.039","article-title":"An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme","volume":"145","author":"Ceccarelli","year":"2011","journal-title":"Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2012-02-406074","article-title":"Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A","volume":"120","author":"Pulvino","year":"2012","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5070573","article-title":"PYR-41 and Thalidomide Impair Dendritic Cell Cross-Presentation by Inhibiting Myddosome Formation and Attenuating the Endosomal Recruitments of p97 and Sec61 via NF-\u03baB Inactivation","volume":"2018","author":"You","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2012.44.0958","article-title":"Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies","volume":"31","author":"Micel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1078-0432.CCR-15-1338","article-title":"Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924\/MLN4924) in Patients with Advanced Solid Tumors","volume":"22","author":"Sarantopoulos","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1073\/pnas.90.6.2112","article-title":"Identification and preliminary characterization of a protein motif related to the zinc finger","volume":"90","author":"Lovering","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbamcr.2013.05.026","article-title":"RING-type E3 ligases: Master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination","volume":"1843","author":"Metzger","year":"2014","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.molcel.2007.06.001","article-title":"DCAFs, the Missing Link of the CUL4-DDB1 Ubiquitin Ligase","volume":"26","author":"Lee","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_97","first-page":"227","article-title":"Structural basis for the subunit assembly of the anaphase-promoting complex","volume":"470","author":"Schreiber","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nsmb.2780","article-title":"New insights into ubiquitin E3 ligase mechanism","volume":"21","author":"Berndsen","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrm2690","article-title":"Physiological functions of the HECT family of ubiquitin ligases","volume":"10","author":"Rotin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Wang, Y., Argiles-Castillo, D., Kane, E.I., Zhou, A., and Spratt, D.E. (2020). Erratum: HECT E3 ubiquitin ligases\u2014Emerging insights into their biological roles and disease relevance. J. Cell Sci., 133.","DOI":"10.1242\/jcs.228072"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: Implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/blood-2005-11-4465","article-title":"Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"107","author":"Secchiero","year":"2006","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood-2008-11-187708","article-title":"Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism","volume":"113","author":"Secchiero","year":"2009","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/leu.2008.11","article-title":"MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM","volume":"22","author":"Gu","year":"2008","journal-title":"Leukemia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/leu.2013.345","article-title":"Blocking ETV6\/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia","volume":"28","author":"Kaindl","year":"2013","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/1535-7163.MCT-15-0237","article-title":"Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model","volume":"14","author":"Bailey","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"655","DOI":"10.15252\/emmm.201606940","article-title":"Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers","volume":"9","author":"Tosoni","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/1061186X.2019.1570518","article-title":"MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: Effective synergism against human glioblastoma via p53 re-activation","volume":"27","author":"Sarisozen","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00280-015-2830-8","article-title":"Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors","volume":"76","author":"Patnaik","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study","volume":"13","author":"Blay","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a Potent and Selective p53\u2013MDM2 Inhibitor in Clinical Development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.leukres.2020.106489","article-title":"Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1\/1b study\u22c6","volume":"100","author":"Yee","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0044","article-title":"MIRROS: A randomized, placebo-controlled, Phase III trial of cytarabine \u00b1 idasanutlin in relapsed or refractory acute myeloid leukemia","volume":"16","author":"Montesinos","year":"2020","journal-title":"Futur. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1158\/0008-5472.CAN-14-0799","article-title":"SAR405838: An Optimized Inhibitor of MDM2\u2013p53 Interaction That Induces Complete and Durable Tumor Regression","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours","volume":"76","author":"Dickson","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41416-018-0355-8","article-title":"A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours","volume":"120","author":"Langenberg","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2016.07.004","article-title":"A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory\/recurrent acute myelogenous leukemia (AML)","volume":"48","author":"Ravandi","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2016.70.7117","article-title":"Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors","volume":"35","author":"Wagner","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/jm401753e","article-title":"Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2\u2013p53 Inhibitor in Clinical Development","volume":"57","author":"Sun","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1535-7163.MCT-14-0710","article-title":"The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents","volume":"14","author":"Canon","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1158\/1535-7163.MCT-14-1056-T","article-title":"Small Molecule Inhibition of MDM2\u2013p53 Interaction Augments Radiation Response in Human Tumors","volume":"14","author":"Werner","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","article-title":"Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Erba","year":"2019","journal-title":"Blood Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10637-019-00840-1","article-title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma","volume":"38","author":"Gluck","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.18632\/oncotarget.23409","article-title":"Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma","volume":"9","author":"Arnhold","year":"2017","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1200\/JCO.2018.36.15_suppl.11514","article-title":"A phase 1 study of MDM2 inhibitor DS-3032b in patients with well\/de-differentiated liposarcoma (WD\/DD LPS), solid tumors (ST) and lymphomas (L)","volume":"36","author":"Bauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V128.22.593.593","article-title":"Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies\u2014Preliminary Results","volume":"128","author":"Dinardo","year":"2016","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1158\/0008-5472.CAN-18-0338","article-title":"Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53\u2013MDM2 Inhibitor HDM201","volume":"78","author":"Jeay","year":"2018","journal-title":"Cancer Res."},{"key":"ref_131","first-page":"4855","article-title":"Abstract 4855: Discovery of NVP-HDM201\u2014First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics","volume":"76","author":"Holzer","year":"2016","journal-title":"Cancer Chem."},{"key":"ref_132","first-page":"1224","article-title":"Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials","volume":"76","author":"Ferretti","year":"2016","journal-title":"Exp. Mol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","article-title":"Discovery of 4-((3\u2032R,4\u2032S,5\u2032R)-6\u2033-Chloro-4\u2032-(3-chloro-2-fluorophenyl)-1\u2032-ethyl-2\u2033-oxodispiro[cyclohexane-1,2\u2032-pyrrolidine-3\u2032,3\u2033-indoline]-5\u2032-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115\/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development","volume":"60","author":"Aguilar","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2019.37.15_suppl.3126","article-title":"A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors","volume":"37","author":"Rasco","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2020.38.15_suppl.3512","article-title":"Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors","volume":"38","author":"Tolcher","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1021\/acs.jmedchem.5b00810","article-title":"Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors","volume":"58","author":"Holzer","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","article-title":"PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis","volume":"24","author":"Bykov","year":"2005","journal-title":"Oncogene"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1038\/bcj.2016.60","article-title":"An open-label phase I dose-finding study of APR-246 in hematological malignancies","volume":"6","author":"Deneberg","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1021\/jm051122a","article-title":"Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2\u2212p53 Interaction","volume":"49","author":"Ding","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1073\/pnas.0708917105","article-title":"Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition","volume":"105","author":"Shangary","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1087057108315038","article-title":"Identification of Inhibitors for MDM2 Ubiquitin Ligase Activity from Natural Product Extracts by a Novel High-Throughput Electrochemiluminescent Screen","volume":"13","author":"Sasiela","year":"2008","journal-title":"J. Biomol. Screen."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53\u2013HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3748\/wjg.v11.i19.2927","article-title":"Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells","volume":"11","author":"Li","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1535-7163.MCT-08-0063","article-title":"Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2","volume":"7","author":"Kitagaki","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2159-8290.CD-11-0104","article-title":"Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay","volume":"1","author":"Herman","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/1535-7163.MCT-10-0581","article-title":"A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis","volume":"10","author":"Wang","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-12-0066","article-title":"Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis","volume":"11","author":"Huang","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.1646","article-title":"An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase","volume":"28","author":"Orlicky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2007-09-112904","article-title":"Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Rico-Bautista, E., Yang, C.-C., Lu, L., Roth, G.P., and A Wolf, D. (2010). Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol., 8.","DOI":"10.1186\/1741-7007-8-153"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.chembiol.2012.09.015","article-title":"Specific Small Molecule Inhibitors of Skp2-Mediated p27 Degradation","volume":"19","author":"Wu","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2013.06.048","article-title":"Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression","volume":"154","author":"Chan","year":"2013","journal-title":"Cell"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1038\/cddis.2014.66","article-title":"Longikaurin A, a natural ent-kaurane, induces G2\/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS\/JNK\/c-Jun pathway in hepatocellular carcinoma cells","volume":"5","author":"Liao","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1021\/jf201096v","article-title":"1,2,3,4,6-Penta-O-galloyl-\u03b2-d-glucose, Quercetin, Curcumin and Lycopene Induce Cell-Cycle Arrest in MDA-MB-231 and BT474 Cells through Downregulation of Skp2 Protein","volume":"59","author":"Huang","year":"2011","journal-title":"J. Agric. Food Chem."},{"key":"ref_157","first-page":"1949","article-title":"Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells","volume":"6","author":"Su","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"18027","DOI":"10.18632\/oncotarget.4090","article-title":"Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2015.05.005","article-title":"Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy","volume":"364","author":"James","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jn\/nxz029","article-title":"Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial","volume":"149","author":"Howells","year":"2019","journal-title":"J. Nutr."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Blees, J.S., Bokesch, H.R., R\u00fcbsamen, D., Schulz, K., Milke, L., Bajer, M.M., Gustafson, K.R., Henrich, C.J., McMahon, J.B., and Colburn, N.H. (2012). Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase \u03b2-TrCP1. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046567"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1021\/jm300060k","article-title":"Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)","volume":"55","author":"Flygare","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"115080","DOI":"10.1016\/j.taap.2020.115080","article-title":"The SMAC mimetic LCL161 is a direct ABCB1\/MDR1-ATPase activity modulator and BIRC5\/Survivin expression down-regulator in cancer cells","volume":"401","author":"Chang","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2014.06.006","article-title":"Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells","volume":"351","author":"Tian","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6103-5","article-title":"Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice","volume":"19","author":"Shekhar","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","article-title":"Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients with Advanced Solid Tumors","volume":"32","author":"Infante","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1021\/jm101505d","article-title":"A Potent and Orally Active Antagonist (SM-406\/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment","volume":"54","author":"Cai","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00595-010-4390-1","article-title":"Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer","volume":"41","author":"Miura","year":"2011","journal-title":"Surg. Today"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4161\/cbt.20563","article-title":"AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer","volume":"13","author":"Brunckhorst","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00280-015-2709-8","article-title":"Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study","volume":"75","author":"Hurwitz","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1470-2045(20)30327-2","article-title":"Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: A double-blind, multicentre, randomised, phase 2 study","volume":"21","author":"Sun","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/13543784.2013.789498","article-title":"XIAP antisense therapy with AEG 35156 in acute myeloid leukemia","volume":"22","author":"Katragadda","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/jco.2012.30.15_suppl.4105","article-title":"Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)","volume":"30","author":"Lee","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1158\/1538-7445.AM2016-3020","article-title":"Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity","volume":"76","author":"Zhou","year":"2016","journal-title":"Cancer Res."},{"key":"ref_176","first-page":"A25","article-title":"Abstract A25: Phase 1 PK\/PD analysis of the Smac-mimetic TL32711 demonstrates potent and sustained cIAP1 suppression in patient PBMCs and tumor biopsies","volume":"10","author":"Graham","year":"2011","journal-title":"Apoptosis Necrosis Autophagy"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","article-title":"A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"24","author":"Kelly","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"13191","DOI":"10.1074\/jbc.RA118.002649","article-title":"Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity","volume":"293","author":"Brenke","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/ni.2565","article-title":"A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation","volume":"14","author":"Chen","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.4049\/jimmunol.1300456","article-title":"Targeting F Box Protein Fbxo3 to Control Cytokine-Driven Inflammation","volume":"191","author":"Mallampalli","year":"2013","journal-title":"J. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1074\/jbc.RA118.003822","article-title":"A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases","volume":"294","author":"Tian","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.15252\/emmm.201403927","article-title":"Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE 1 ubiquitin ligase","volume":"6","author":"Peter","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1038\/s41388-020-1345-x","article-title":"The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma","volume":"39","author":"Crawford","year":"2020","journal-title":"Oncogene"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2019.10.046","article-title":"A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth","volume":"470","author":"Celegato","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Cherry, J.J., Rietz, A., Malinkevich, A., Liu, Y., Xie, M., Bartolowits, M., Davisson, V.J., Baleja, J.D., and Androphy, E.J. (2013). Structure Based Identification and Characterization of Flavonoids That Disrupt Human Papillomavirus-16 E6 Function. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0084506"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/BJ20121651","article-title":"The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system","volume":"451","author":"Strickson","year":"2013","journal-title":"Biochem. J."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00535-013-0848-4","article-title":"BAY 11-7082, a nuclear factor-\u03baB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells","volume":"49","author":"Chen","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbrc.2018.12.164","article-title":"Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-\u03baB signaling","volume":"509","author":"Katsuya","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42003-020-0882-8","article-title":"Molecular bases for HOIPINs-mediated inhibition of LUBAC and innate immune responses","volume":"3","author":"Oikawa","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd2596","article-title":"Bendamustine","volume":"7","author":"Keating","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/annonc\/mdf189","article-title":"Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"13","author":"Weidmann","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"Weidmann","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.24430","article-title":"A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL","volume":"91","author":"Flinn","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.onc.1201459","article-title":"p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding","volume":"15","author":"Midgley","year":"1997","journal-title":"Oncogene"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.onc.1210707","article-title":"HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function","volume":"27","author":"Lau","year":"2007","journal-title":"Oncogene"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/sj.onc.1208814","article-title":"Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway","volume":"24","author":"Zhang","year":"2005","journal-title":"Oncogene"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1016\/j.bmcl.2016.08.010","article-title":"Discovery of a novel class of highly potent inhibitors of the p53\u2013MDM2 interaction by structure-based design starting from a conformational argument","volume":"26","author":"Furet","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrd4432","article-title":"SCF ubiquitin ligase-targeted therapies","volume":"13","author":"Skaar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc3700","article-title":"Roles of F-box proteins in cancer","volume":"14","author":"Wang","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Yumimoto, K., Yamauchi, Y., and Nakayama, K.I. (2020). F-Box Proteins and Cancer. Cancers, 12.","DOI":"10.3390\/cancers12051249"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.1645","article-title":"Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase","volume":"28","author":"Aghajan","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The tor pathway: A target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"mTOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Cloughesy, T.F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., and Youngkin, D. (2008). Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050008"},{"key":"ref_210","first-page":"2178","article-title":"Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells","volume":"6","author":"Su","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"66512","DOI":"10.18632\/oncotarget.11614","article-title":"Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells","volume":"7","author":"Yin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"41809","DOI":"10.18632\/oncotarget.6166","article-title":"Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"102570","DOI":"10.1016\/j.ebiom.2019.11.031","article-title":"Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth","volume":"51","author":"Zhou","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Benary, U., and Wolf, J. (2019). Wolf Controlling Nuclear NF-\u03baB Dynamics by \u03b2-TrCP\u2014Insights from a Computational Model. Biomedicine, 7.","DOI":"10.3390\/biomedicines7020040"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrd2056","article-title":"Drug discovery in the ubiquitin\u2013proteasome system","volume":"5","author":"Nalepa","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/0008-5472.CAN-04-1626","article-title":"Increased Expression of the E3-Ubiquitin Ligase Receptor Subunit \u03b2TRCP1 Relates to Constitutive Nuclear Factor-\u03baB Activation and Chemoresistance in Pancreatic Carcinoma Cells","volume":"65","author":"Arlt","year":"2005","journal-title":"Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbrc.2008.01.166","article-title":"A novel small-molecule inhibitor of NF-\u03baB signaling","volume":"368","author":"Nakajima","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nsmb.2108","article-title":"Mechanism of ubiquitylation by dimeric RING ligase RNF4","volume":"18","author":"Jaffray","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10495-007-0087-3","article-title":"The inhibitors of apoptosis (IAPs) as cancer targets","volume":"12","author":"Hunter","year":"2007","journal-title":"Apoptosis"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2007.10.042","article-title":"Smac Mimetics and TNF\u03b1: A Dangerous Liaison?","volume":"131","author":"Wu","year":"2007","journal-title":"Cell"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2010.11.016","article-title":"Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?","volume":"143","author":"Cohen","year":"2010","journal-title":"Cell"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1006\/excr.1999.4733","article-title":"Tumor Necrosis Factor Receptor-Associated Factor (TRAF) Family: Adapter Proteins That Mediate Cytokine Signaling","volume":"254","author":"Inoue","year":"2000","journal-title":"Exp. Cell Res."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0898-6568(01)00160-7","article-title":"The TNF-receptor-associated factor family: Scaffold molecules for cytokine receptors, kinases and their regulators","volume":"13","author":"Wajant","year":"2001","journal-title":"Cell. Signal."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-2187-8-7","article-title":"TRAF molecules in cell signaling and in human diseases","volume":"8","author":"Xie","year":"2013","journal-title":"J. Mol. Signal."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1007\/s00018-010-0464-x","article-title":"Deciphering the complexity of Toll-like receptor signaling","volume":"67","author":"Ostuni","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1172\/JCI58818","article-title":"TRAF6 is an amplified oncogene bridging the RAS and NF-\u03baB pathways in human lung cancer","volume":"121","author":"Starczynowski","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-012-1434-4","article-title":"TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell","volume":"371","author":"Meng","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13277-012-0543-8","article-title":"Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell","volume":"34","author":"Zhong","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Owais, A., Mishra, R.K., and Kiyokawa, H. (2020). The HECT E3 ligase E6AP\/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders. Cancers, 12.","DOI":"10.3390\/cancers12082108"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"17677","DOI":"10.1002\/chem.201804169","article-title":"Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors","volume":"24","author":"Watt","year":"2018","journal-title":"Chem. A Eur. J."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/ncomms5901","article-title":"ATR\/Chk1\/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-018-0470-0","article-title":"Ubiquitination by HUWE1 in tumorigenesis and beyond","volume":"25","author":"Kao","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Ricci-L\u00f3pez, J., Vidal-Limon, A., Zun\u00f1iga, M., Jim\u00e8nez, V.A., Alderete, J.B., Brizuela, C.A., and Aguila, S. (2019). Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213028"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/13543776.2018.1549229","article-title":"A patent review of the ubiquitin ligase system: 2015\u20132018","volume":"28","author":"Li","year":"2018","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.chembiol.2011.09.013","article-title":"Natural Product-Like Macrocyclic N-Methyl-Peptide Inhibitors against a Ubiquitin Ligase Uncovered from a Ribosome-Expressed De Novo Library","volume":"18","author":"Yamagishi","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"16736","DOI":"10.1073\/pnas.1412152111","article-title":"Peptide and small molecule inhibitors of HECT-type ubiquitin ligases","volume":"111","author":"Mund","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semcancer.2020.05.002","article-title":"RBR E3 ubiquitin ligases in tumorigenesis","volume":"67","author":"Wang","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1038\/sj.emboj.7601360","article-title":"A ubiquitin ligase complex assembles linear polyubiquitin chains","volume":"25","author":"Kirisako","year":"2006","journal-title":"EMBO J."},{"key":"ref_239","first-page":"591","article-title":"Linear ubiquitination prevents inflammation and regulates immune signalling","volume":"471","author":"Gerlach","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_240","first-page":"637","article-title":"SHARPIN forms a linear ubiquitin ligase complex regulating NF-\u03baB activity and apoptosis","volume":"471","author":"Ikeda","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_241","first-page":"633","article-title":"SHARPIN is a component of the NF-\u03baB-activating linear ubiquitin chain assembly complex","volume":"471","author":"Tokunaga","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2159-8290.CD-13-0915","article-title":"Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms","volume":"4","author":"Yang","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/cb500653y","article-title":"Gliotoxin Suppresses NF-\u03baB Activation by Selectively Inhibiting Linear Ubiquitin Chain Assembly Complex (LUBAC)","volume":"10","author":"Sakamoto","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.chembiol.2018.06.004","article-title":"The MALDI-TOF E2\/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway","volume":"25","author":"Johnson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/jacs.8b13193","article-title":"Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP","volume":"141","author":"Johansson","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.chembiol.2019.11.007","article-title":"Single-Domain Antibodies as Crystallization Chaperones to Enable Structure-Based Inhibitor Development for RBR E3 Ubiquitin Ligases","volume":"27","author":"Tsai","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbamcr.2013.06.027","article-title":"Regulation of proteolysis by human deubiquitinating enzymes","volume":"1843","author":"Eletr","year":"2014","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.febslet.2013.11.003","article-title":"Development of inhibitors in the ubiquitination cascade","volume":"588","author":"Zhang","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1535-7163.MCT-09-0097","article-title":"Small-molecule inhibitor of USP7\/HAUSP ubiquitin protease stabilizes and activates p53 in cells","volume":"8","author":"Colland","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_250","first-page":"648","article-title":"Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization","volume":"416","author":"Li","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","article-title":"A Dynamic Role of HAUSP in the p53-Mdm2 Pathway","volume":"13","author":"Li","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.chembiol.2012.02.007","article-title":"Discovery of Specific Inhibitors of Human USP7\/HAUSP Deubiquitinating Enzyme","volume":"19","author":"Reverdy","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1021\/ml200276j","article-title":"Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47","volume":"3","author":"Weinstock","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1038\/cddis.2013.400","article-title":"USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.chembiol.2011.08.018","article-title":"Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes","volume":"18","author":"Altun","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.chembiol.2017.09.004","article-title":"USP7-Specific Inhibitors Target and Modify the Enzyme\u2019s Active Site via Distinct Chemical Mechanisms","volume":"24","author":"Pozhidaeva","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jmcb\/mjw049","article-title":"Modulation of the p53\/MDM2 interplay by HAUSP inhibitors","volume":"9","author":"Tavana","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nchembio.2528","article-title":"Discovery and characterization of highly potent and selective allosteric USP7 inhibitors","volume":"14","author":"Gavory","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"10056","DOI":"10.1021\/acs.jmedchem.7b01293","article-title":"Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques","volume":"60","author":"Pastor","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2017.09.003","article-title":"Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7","volume":"24","author":"Lamberto","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.chembiol.2011.08.014","article-title":"Selective and Cell-Active Inhibitors of the USP1\/ UAF1 Deubiquitinase Complex Reverse Cisplatin Resistance in Non-small Cell Lung Cancer Cells","volume":"18","author":"Chen","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_264","doi-asserted-by":"crossref","unstructured":"Kobayashi, E., Hwang, D., Bheda-Malge, A., Whitehurst, C.B., Kabanov, A.V., Kondo, S., Aga, M., Yoshizaki, T., Pagano, J.S., and Sokolsky, M. (2019). Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153733"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","article-title":"Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies","volume":"125","author":"Peterson","year":"2015","journal-title":"Blood"},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Clancy, A., Heride, C., Pinto-Fern\u00e1ndez, A., Elcocks, H., Kallinos, A., Kayser-Bricker, K.J., Wang, W., Smith, V., Davis, S., and Fessler, S. (2021). The deubiquitylase USP9X controls ribosomal stalling. J. Cell Biol., 220.","DOI":"10.1083\/jcb.202004211"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nchembio.2557","article-title":"Allosteric inhibitors hit USP7 hard","volume":"14","author":"Zhang","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_268","first-page":"534","article-title":"USP7 small-molecule inhibitors interfere with ubiquitin binding","volume":"550","author":"Kategaya","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.molcel.2007.09.031","article-title":"A UAF1-Containing Multisubunit Protein Complex Regulates the Fanconi Anemia Pathway","volume":"28","author":"Cohn","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1101\/gad.1955310","article-title":"Expanded roles of the Fanconi anemia pathway in preserving genomic stability","volume":"24","author":"Kee","year":"2010","journal-title":"Genes Dev."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"19209","DOI":"10.1074\/jbc.M117.815126","article-title":"An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons","volume":"292","author":"Boselli","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4049\/jimmunol.1700273","article-title":"Inhibition of the Deubiquitinase Usp14 Diminishes Direct MHC Class I Antigen Presentation","volume":"200","author":"Palmer","year":"2018","journal-title":"J. Immunol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s10495-019-01561-9","article-title":"Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma","volume":"24","author":"Sha","year":"2019","journal-title":"Apoptosis"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.1075898","article-title":"Role of Rpn11 Metalloprotease in Deubiquitination and Degradation by the 26S Proteasome","volume":"298","author":"Verma","year":"2002","journal-title":"Science"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1021\/acs.jmedchem.6b01379","article-title":"Discovery of an Inhibitor of the Proteasome Subunit Rpn11","volume":"60","author":"Perez","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nchembio.2370","article-title":"Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases","volume":"13","author":"Lauinger","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1021\/acschembio.7b00543","article-title":"Cell Lysate-Based AlphaLISA Deubiquitinase Assay Platform for Identification of Small Molecule Inhibitors","volume":"12","author":"Ott","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.chembiol.2003.08.010","article-title":"Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line","volume":"10","author":"Liu","year":"2003","journal-title":"Chem. Biol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"16825","DOI":"10.1021\/jacs.0c07726","article-title":"A Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos","volume":"142","author":"Kooij","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Peddaboina, C., Jupiter, D., Fletcher, S., Yap, J.L., Rai, A., Tobin, R.P., Jiang, W., Rascoe, P., Rogers, M.K.N., and Smythe, W.R. (2012). The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-541"},{"key":"ref_281","first-page":"103","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Schwickart","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cellsig.2011.08.002","article-title":"A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination","volume":"23","author":"Kapuria","year":"2011","journal-title":"Cell. Signal."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1073\/pnas.1322198111","article-title":"Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1074\/jbc.M109.074971","article-title":"Regulation of Virus-triggered Signaling by OTUB1- and OTUB2-mediated Deubiquitination of TRAF3 and TRAF6","volume":"285","author":"Li","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00125-013-2889-x","article-title":"Otubain 2 is a novel promoter of beta cell survival as revealed by siRNA high-throughput screens of human pancreatic islets","volume":"56","author":"Beck","year":"2013","journal-title":"Diabetologia"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1093\/hmg\/ddq232","article-title":"Integrative gene\u2013tissue microarray-based approach for identification of human disease biomarkers: Application to amyotrophic lateral sclerosis","volume":"19","author":"Kudo","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molcel.2018.10.030","article-title":"OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ","volume":"73","author":"Zhang","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2013.05.046","article-title":"OTU Deubiquitinases Reveal Mechanisms of Linkage Specificity and Enable Ubiquitin Chain Restriction Analysis","volume":"154","author":"Mevissen","year":"2013","journal-title":"Cell"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/jacs.9b02822","article-title":"Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening","volume":"141","author":"Resnick","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"15203","DOI":"10.1038\/ncomms15203","article-title":"Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity","volume":"8","author":"Bednash","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1158\/0008-5472.CAN-06-0702","article-title":"Identification of New Compounds That Trigger Apoptosome-Independent Caspase Activation and Apoptosis","volume":"66","author":"Aleo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Reiner, T., Parrondo, R., Pozas, A.D.L., Palenzuela, D., and Perez-Stable, C. (2013). Betulinic Acid Selectively Increases Protein Degradation and Enhances Prostate Cancer-Specific Apoptosis: Possible Role for Inhibition of Deubiquitinase Activity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056234"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"Wang","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cbpa.2009.08.003","article-title":"Identifying druggable disease-modifying gene products","volume":"13","author":"Dixon","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S1359-6446(05)03666-4","article-title":"The druggable genome: An update","volume":"10","author":"Russ","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted Protein Degradation: From Chemical Biology to Drug Discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: New Approaches to Protein Degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_299","first-page":"1001","article-title":"Reaching for high-hanging fruit in drug discovery at protein\u2013protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs)\u2014Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.febslet.2013.12.025","article-title":"Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation","volume":"588","author":"Leiser","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nchembio.1560","article-title":"Small-molecule modulation of Ras signaling","volume":"10","author":"Spiegel","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/25159","article-title":"Identification of the receptor component of the IkBa-ubiquitin ligase","volume":"396","author":"Yaron","year":"1998","journal-title":"Nature"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell. Proteom."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a Primary Target of Thalidomide Teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel\u2013Lindau E3 Ubiquitin Ligase Using Small Molecules to Disrupt the VHL\/HIF-1\u03b1 Interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"11463","DOI":"10.1002\/anie.201206231","article-title":"Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1\u03b1","volume":"51","author":"Buckley","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.chembiol.2012.08.015","article-title":"Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1\u03b1 Protein-Protein Interface","volume":"19","author":"Thomann","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1021\/jm5011258","article-title":"Structure-Guided Design and Optimization of Small Molecules Targeting the Protein\u2013Protein Interaction between the von Hippel\u2013Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities","volume":"57","author":"Galdeano","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/acschembio.5b00442","article-title":"HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins","volume":"10","author":"Buckley","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_319","first-page":"524","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.1422165112","article-title":"An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma","volume":"112","author":"Baratta","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_325","doi-asserted-by":"crossref","unstructured":"Ishikawa, M., Tomoshige, S., Demizu, Y., and Naito, M. (2020). Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs. Pharmaceuticals, 13.","DOI":"10.3390\/ph13040074"},{"key":"ref_326","first-page":"50","article-title":"Proteolysis targeting chimeras (PROTACs) in cancer therapy","volume":"13","author":"Pandiella","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"126877","DOI":"10.1016\/j.bmcl.2019.126877","article-title":"Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties","volume":"30","author":"Buhimschi","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.bmcl.2018.05.057","article-title":"Development of the first small molecule histone deacetylase 6 (HDAC6) degraders","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1039\/C9CC08509B","article-title":"Plasticity in designing PROTACs for selective and potent degradation of HDAC6","volume":"55","author":"Yang","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1021\/acschembio.8b00705","article-title":"Modulating PCAF\/GCN5 Immune Cell Function through a PROTAC Approach","volume":"13","author":"Bassi","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/acschembio.8b00698","article-title":"Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC to Provide Insight into Small Molecule Targeting of BCL","volume":"13","author":"McCoull","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-16-2622","article-title":"Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer","volume":"77","author":"Bai","year":"2017","journal-title":"Cancer Res."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation Accession codes Atomic coordinates and structure factors for hsBrd4 BD2-MZ1-hsVHL-hsEloC-hsEloB have been deposited in the Protein Data Bank (PDB) under accession number","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1021\/acs.jmedchem.7b00635","article-title":"Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase","volume":"61","author":"Crew","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41589-018-0010-y","article-title":"Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands","volume":"14","author":"Gechijian","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1021\/jacs.8b10320","article-title":"Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion","volume":"140","author":"Burslem","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbrc.2018.09.169","article-title":"Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)","volume":"505","author":"Kang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acsmedchemlett.9b00219","article-title":"Targeting IRAK4 for Degradation with PROTACs","volume":"10","author":"Nunes","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"112186","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","article-title":"MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53","volume":"79","author":"Hines","year":"2019","journal-title":"Cancer Res."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1039\/C8CC07813K","article-title":"Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","article-title":"Harnessing the anti-cancer natural product nimbolide for targeted protein degradation","volume":"15","author":"Spradlin","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_357","first-page":"5236","article-title":"Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer","volume":"78","author":"Neklesa","year":"2018","journal-title":"Clin. Trials"},{"key":"ref_358","first-page":"P5-04","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Poster Sess. Abstr."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein Knockdown Using Methyl Bestatin\u2212Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins","volume":"132","author":"Itoh","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2018.12.002","article-title":"SNIPERs\u2014Hijacking IAP activity to induce protein degradation","volume":"31","author":"Naito","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1016\/j.bmc.2011.03.057","article-title":"Development of target protein-selective degradation inducer for protein knockdown","volume":"19","author":"Itoh","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/cas.12272","article-title":"Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells","volume":"104","author":"Okuhira","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1074\/jbc.RA117.001091","article-title":"Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor \u03b1 degradation","volume":"293","author":"Ohoka","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acs.jmedchem.7b00168","article-title":"Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands","volume":"61","author":"Shibata","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1248\/cpb.c18-00567","article-title":"Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)","volume":"67","author":"Ohoka","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: Bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the Chemical Knockdown of Cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"eaay5154","DOI":"10.1126\/sciadv.aay5154","article-title":"\u00dcmit; et al. Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: A safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ddtec.2019.02.005","article-title":"Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations","volume":"31","author":"Watt","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: Expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_378","doi-asserted-by":"crossref","unstructured":"Roy, R.D., Rosenmund, C., and Stefan, M. (2017). Cooperative binding mitigates the high-dose hook effect. BMC Syst. Biol., 11.","DOI":"10.1186\/s12918-017-0447-8"},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: A critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor. Target. Anti-tumor Ther."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Fink","year":"2015","journal-title":"Nature"},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"Pan","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"ref_385","first-page":"49","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies","volume":"25","author":"Rasco","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1073\/pnas.89.9.4037","article-title":"Antiestrogen ICI 164, 384 Reduces Cellular Estrogen Receptor Content by Increasing Its Turnover","volume":"89","author":"Dauvois","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/nchembio.1658","article-title":"Pharmacological targeting of the pseudokinase Her3","volume":"10","author":"Xie","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1002\/anie.201503720","article-title":"Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging","volume":"54","author":"Gustafson","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1074\/jbc.M113.544825","article-title":"Ubiquibodies, Synthetic E3 Ubiquitin Ligases Endowed with Unnatural Substrate Specificity for Targeted Protein Silencing","volume":"289","author":"Portnoff","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.chembiol.2012.04.008","article-title":"Inhibitor Mediated Protein Degradation","volume":"19","author":"Long","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41592-020-00992-6","article-title":"Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies","volume":"17","author":"Kanner","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1126\/science.1230161","article-title":"A Strategy for Modulation of Enzymes in the Ubiquitin System","volume":"339","author":"Ernst","year":"2013","journal-title":"Science"},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.4161\/cc.24985","article-title":"Engineering ubiquitin to modulate the ubiquitin proteosome system","volume":"12","author":"Ernst","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nchembio.1134","article-title":"Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7","volume":"9","author":"Zhang","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jmb.2017.05.025","article-title":"Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10","volume":"429","author":"Zhang","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jmb.2019.09.024","article-title":"Structural and Functional Analysis of Ubiquitin-based Inhibitors That Target the Backsides of E2 Enzymes","volume":"432","author":"Garg","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/febs.15536","article-title":"Targeted modulation of E3 ligases using engineered ubiquitin variants","volume":"288","author":"LeBlanc","year":"2021","journal-title":"FEBS J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:19:48Z","timestamp":1760163588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/3079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":401,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13123079"],"URL":"https:\/\/doi.org\/10.3390\/cancers13123079","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,20]]}}}